×
  • News
  • Updated: October 24, 2022

Augmentin: Why NAFDAC Issued Warning Against Popular Drug  

Augmentin: Why NAFDAC Issued Warning Against Popular Drug  �

Nigerians have been warned by the National Agency for Food and Drugs Administration and Control (NAFDAC) over suspected counterfeit Augmentin 625mg Tabs in the country.

NAFDAC gave the warning because the product fell short of the labelling requirements.

The agency gave the alert on its website titled ‘NAFDAC Alert And Sensitization Of The Public On Suspected Falsified Augmentin 625mg

According to NAFDAC, the suspected falsified Augmentin has batch number 562626, with a NAFDAC registration number- 04-1928, and was manufactured in April 2021 and would expire in April 2024.

“The product failed short of the labelling requirements. No inscription “manufactured by” is written on the label, only the address.

“Manufacturing and Expiry dates do not meet the acceptable format. No MAS scratch number for verification.

“The logo “gsk” is not properly positioned as on the original. The listed information indicates the product is falsified and counterfeited.

“In view of the above, NAFDAC has notified all its formations in the zones and 36 states of the federation including the FCT to carry out surveillance and mop up the falsified Augmentin tablets.”

It added, “Please note that the genuine Augmentin 625mg has legible product labelling information including date markings – expiration and manufactured dates, batch number and NAFDAC registration number.

“NAFDAC advises wholesalers, distributors, and pharmacies that medicines should be obtained from authorized/licensed suppliers, increased vigilance is hereby encouraged within the supply chain to avoid infiltration of the falsified product.

"The products’ authenticity, physical condition and labels should be carefully checked.

“NAFDAC implores healthcare providers to ensure vigilance to prevent the administration of falsified products to unsuspecting patients.

"Members of the public in possession of the above suspected counterfeit product are advised to discontinue sale or use and submit stock to the nearest NAFDAC office.

“Healthcare providers and the public should notify the nearest NAFDAC office of any information concerning the distribution, sale, and use of the falsified version of the Augmentin product."

Related Topics

Join our Telegram platform to get news update Join Now

0 Comment(s)

See this post in...

Notice

We have selected third parties to use cookies for technical purposes as specified in the Cookie Policy. Use the “Accept All” button to consent or “Customize” button to set your cookie tracking settings